COVID-19 infection in tuberculosis patients in the municipality of Chisinau
Keywords:
COVID-19, SARS- CoV-2, tuberculosis, HIV infection, CoinfectionAbstract
Thanks to the combined efforts of the states and medical communities, in recent years it has been possible to stabilize for tuberculosis. 2020 brought a new challenge to humanity in the form of a previously unknown disease pandemic - COVID-19 infection. Economic crises, a decrease in the standard of living among broad sections of the population have always had an adverse effect on the epidemiological indicators of tuberculosis, so a similar negative impact on them should be expected now. To attempt to analyze the demographic structure, clinical and radiological forms of tuberculosis and COVID-19. Examination and treatment of 63 patients were carried out in 2020 in the Municipal Clinical Hospital of Phtisiopneumology. Tuberculosis, confirmed by conventional bacteriological and molecular-genetic methods. The coronavirus infection was verified by a positive polymerase chain reaction test for SARS-CoV-2. Tuberculosis in 43 patients was detected simultaneously with COVID-19, in 20 people coronavirus infection was diagnosed in TB patients. Disseminated forms of tuberculosis prevailed - 50.8%; in 36.5%, two or more organs and systems were affected, which is associated with a high proportion (54.0%) of HIV-positive patients. Lung damage with COVID-19 was noted in 36.5%. Fatal outcomes ended in 20.6% of cases of coinfection. An assumption was made about the possibility of an aggravating effect of tuberculosis on COVID-19 in the case of severe or widespread forms of these diseases.
References
1. Wang Y, Xu J, Wang Y, Hou H, Shi L, Yang H. Prevalence of comorbid tuberculosis amongst COVID- 19 patients: A rapid review and meta- analysis. In: Int J Clin Pract. 2021;75:e14867. https://doi.org/10.1111/ijcp.14867
2. Wang Y, Feng R, Xu J, Hou H, Feng H, Yang H. An updated metaanalysis on the association between tuberculosis and COVID-19 severity and mortality. In: J Med Virol. 2021;93(10):5682- 5686. https://doi.org/10.1002/jmv.27119
3. Tian J, Yan S, Wang H, et al. Hanshiyi formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: a cohort study. In: Pharmacol Res. 2020; https://doi.org/10.1016/j.phrs.2020.105127
4. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. In: Eur Res J. 2020;55(5). https://doi.org/10.1183/13993003.00524-2020
5. Hu Y, Wang T, Hu Z, et al. Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: a single-center experience. In: Biomed Pharmacother. 2020;130:110529. https://doi.org/10.1016/j.biopha.2020.110529
6. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. In: Clin Infect Dis. 2020.
7. World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/ bitstream/handle/10665/336069/9789240013131en. pdf. Date last accessed: September 19. 202.
8. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. In: N Engl J Med 2020; 382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002032
9. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARSCov-2) outside of Wuhan, China: retrospective case series. In: BMJ 2020;368:m606. https://doi.org/10.1136/bmj.m606
10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. In: Lancet 2020: 395(10229): 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
11. Ong CWM, Migliori GB, Raviglione M, et al. Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members of ESCMID Study Group for Mycobacterial Infections (ESGMYC). In: Eur Respir J 2020: 56(4): 2001727. https://doi.org/10.1183/13993003.01727-2020
12. Migliori GB, Thong PM, Akkerman O, et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. In: Emerg Infect Dis.2020;26(11):2709-2712. https://doi.org/10.3201/eid2611.203163
13. McQuaid C F, Vassall A, Cohen T, et al. The impact of COVID-19 on TB: a review of the data. In: Int J Tuberc Lung Dis 2021; 25(6):436-446. https://doi.org/10.5588/ijtld.21.0148
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
